Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging

Dow Mu Koh, Ahmed Ba-Ssalamah, Giuseppe Brancatelli, Ghaneh Fananapazir, M. Isabel Fiel, Satoshi Goshima, Sheng Hong Ju, Nikolaos Kartalis, Masatoshi Kudo, Jeong Min Lee, Takamichi Murakami, Max Seidensticker, Claude B. Sirlin, Cher Heng Tan, Jin Wang, Jeong Hee Yoon, Mengsu Zeng, Jian Zhou, Bachir Taouli

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Objectives: The 9th International Forum for Liver Magnetic Resonance Imaging (MRI) was held in Singapore in September 2019, bringing together radiologists and allied specialists to discuss the latest developments in and formulate consensus statements for liver MRI, including the applications of gadoxetic acid–enhanced imaging. Methods: As at previous Liver Forums, the meeting was held over 2 days. Presentations by the faculty on days 1 and 2 and breakout group discussions on day 1 were followed by delegate voting on consensus statements presented on day 2. Presentations and discussions centered on two main meeting themes relating to the use of gadoxetic acid–enhanced MRI in primary liver cancer and metastatic liver disease. Results and conclusions: Gadoxetic acid–enhanced MRI offers the ability to monitor response to systemic therapy and to assist in pre-surgical/pre-interventional planning in liver metastases. In hepatocellular carcinoma, gadoxetic acid–enhanced MRI provides precise staging information for accurate treatment decision-making and follow-up post therapy. Gadoxetic acid–enhanced MRI also has potential, currently investigational, indications for the functional assessment of the liver and the biliary system. Additional voting sessions at the Liver Forum debated the role of multidisciplinary care in the management of patients with liver disease, evidence to support the use of abbreviated imaging protocols, and the importance of standardizing nomenclature in international guidelines in order to increase the sharing of scientific data and improve the communication between centers. Key Points: • Gadoxetic acid–enhanced MRI is the preferred imaging method for pre-surgical or pre-interventional planning for liver metastases after systemic therapy. • Gadoxetic acid–enhanced MRI provides accurate staging of HCC before and after treatment with locoregional/biologic therapies. • Abbreviated protocols for gadoxetic acid–enhanced MRI offer potential time and cost savings, but more evidence is necessary. The use of gadoxetic acid–enhanced MRI for the assessment of liver and biliary function is under active investigation.

Original languageEnglish
Pages (from-to)5615-5628
Number of pages14
JournalEuropean Radiology
Issue number8
StatePublished - Aug 2021


  • Gadoxetic acid
  • Hepatocellular carcinoma
  • Magnetic resonance imaging
  • Metastatic liver disease


Dive into the research topics of 'Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging'. Together they form a unique fingerprint.

Cite this